公开(公告)号：WO1998015580A1

公开(公告)日：1998-04-16

申请号：PCT/EP1997005556

申请日：1997-10-09

Applicant: BOEHRINGER MANNHEIM GMBH ,  HÜBNER-PARAJSZ, Christa ,  SCHETTERS, Hartmut ,  KIENTSCH-ENGEL, Rosemarie ,  MEIER, Thomas ,  KAUFMANN, Martin ,  GALLUSSER, Andreas ,  DEEG, Rolf

Inventor： BOEHRINGER MANNHEIM GMBH

IPC: C07K16/38

CPC classification number: C07K14/705 ,  C07K16/38 ,  C07K16/40 ,  G01N33/57434

Abstract: The invention relates to monoclonal antibodies against a human ACT and serine protease complex, preferably ACT-PSA presenting no cross reactivity to free, non-complexed human ACT and free, non-complexed PSA, as well as diagnostic test methods to detect serine protease ACT complexes, using these monoclonal antibodies.

Abstract translation: 本发明涉及一种单克隆抗体针对人ACT的络合物和丝氨酸蛋白酶，优选ACT-PSA基本上没有交叉反应性，以释放，具有非络合的人ACT和自由的，未复合的PSA，以及诊断测试方法用于检测丝氨酸蛋白酶-ACT的 络合物，特别是PSA-ACT使用单克隆抗体。

公开(公告)号：WO9714797A2

公开(公告)日：1997-04-24

申请号：PCT/US9616782

申请日：1996-10-18

Applicant: DANA FARBER CANCER INST INC

Inventor： SOTIROPOULOU GEORGIA ,  ANISOWICZ ANTHONY ,  SAGER RUTH

IPC: A61K38/00 ,  A61K48/00 ,  C07K14/81 ,  C12N1/21 ,  C12N15/15 ,  A01K67/027 ,  A61K38/57 ,  A61K39/395 ,  C07K16/38 ,  C07K19/00 ,  C12N1/19 ,  C12N5/10 ,  C12N15/00 ,  C12N15/11 ,  C12N15/62 ,  C12Q1/68 ,  G01N33/68

CPC classification number: C07K14/8139 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  C07K2319/00

Abstract: Isolated nucleic acid molecules encoding a novel cysteine proteinase inhibitor, cystatin M, which is a member of the Family 2 cystatins, are disclosed. Cystatin M exhibits cysteine proteinase inhibitory activity against papain, is downregulated in metastatic mammary epithelial tumor cells, as well as other tumor cells, and is upregulated in senescent cells. In addition to isolated nucleic acid molecules, the invention provides antisense nucleic acid molecules, recombinant expression vectors containing a nucelic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a cystatin M gene has been introduced or disrupted. The invention further provides isolated cystatin M proteins, fusion proteins, antigenic peptides and anti-cystatin M antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Abstract translation: 公开了编码新型半胱氨酸蛋白酶抑制剂的分离的核酸分子，半胱氨酸蛋白酶抑制剂M是家族2胱氨酸蛋白酶的成员。 半胱氨酸蛋白酶抑制剂M表现出对木瓜蛋白酶的半胱氨酸蛋白酶抑制活性，在转移性乳腺上皮肿瘤细胞以及其他肿瘤细胞中下调，并在衰老细胞中上调。 除了分离的核酸分子之外，本发明提供了反义核酸分子，含有本发明的一种营养酸分子的重组表达载体，已经引入了表达载体的宿主细胞和其中半胱氨酸蛋白酶抑制剂M基因 已被引入或中断。 本发明还提供了分离的半胱氨酸蛋白酶抑制剂M蛋白，融合蛋白，抗原肽和抗半胱氨酸蛋白酶抑制剂M抗体。 还提供利用本发明组合物的诊断，筛选和治疗方法。

公开(公告)号：WO9207254A3

公开(公告)日：1992-06-11

申请号：PCT/EP9101877

申请日：1991-10-01

Applicant: BASF AG

Inventor： LANG KURT ,  SUBKOWSKI THOMAS ,  SCHWEDEN JUERGEN

IPC: A61K38/00 ,  C07K14/00 ,  C07K14/575 ,  C07K14/81 ,  C07K14/815 ,  C07K16/26 ,  C07K16/38 ,  C07K16/44 ,  C12N9/22 ,  G01N27/447 ,  C07K15/00 ,  G01N33/53

CPC classification number: C12N9/22 ,  A61K38/00 ,  C07K14/001 ,  C07K14/57536 ,  C07K14/8117 ,  C07K14/815 ,  C07K16/26 ,  C07K16/38 ,  C07K16/44

Abstract: The use is disclosed of substances that are linked at the intermolecular level by S-S bridges for producing antibodies, as well as the use of these substances as calibrating substances in molecular weight determination.

公开(公告)号：WO2023049501A1

公开(公告)日：2023-03-30

申请号：PCT/US2022/044863

申请日：2022-09-27

Applicant: ABBRATECH INC.

Inventor： WEINER, Michael P.

IPC: C07K16/44 ,  C07K16/08 ,  C07K16/38

Abstract: The present disclosure provides a method of making a site-specific antibody to a target of interest.

公开(公告)号：WO2023013673A1

公开(公告)日：2023-02-09

申请号：PCT/JP2022/029787

申请日：2022-08-03

Applicant: 公立大学法人奈良県立医科大学 ,  東ソー株式会社

Inventor： 小林　浩 ,  中島　有紀 ,  大竹　則久 ,  明庭　昇平

IPC: G01N33/53 ,  C07K14/47 ,  C07K16/18 ,  C07K16/38

Abstract: 悪性腫瘍関連血栓塞栓症を検出する方法、及び前記方法に利用できる試薬を提供することを課題とする。患者由来の検体中のＴＦＰＩ２量を測定することを特徴とする、悪性腫瘍関連血栓塞栓症を検出する方法。また、ＮＴ－ＴＦＰＩ２及びインタクトＴＦＰＩ２を特異的に認識する抗体を悪性腫瘍関連血栓塞栓症の検出試薬に含める。

公开(公告)号：WO2022063913A1

公开(公告)日：2022-03-31

申请号：PCT/EP2021/076230

申请日：2021-09-23

Applicant: NOVO NORDISK A/S

Inventor： JØRGENSEN, Jonas, Oldenburg ,  JONES, Sarah, Elizabeth

IPC: A61K9/00 ,  A61K9/08 ,  A61K47/10 ,  A61K47/26 ,  A61P7/04 ,  A61K39/395 ,  C07K16/38

Abstract: Disclosed herein is a method of preparing a pharmaceutical formulation comprising a preservative, a surfactant and an anti-TFPI antibody (concizumab) as the active pharmaceutical ingredient. Application of the disclosed method results in the pharmaceutical formulation having improved chemical and physical purity. Also disclosed herein is the pharmaceutical formulation obtained using said method and its medical uses.

公开(公告)号：WO2022058261A2

公开(公告)日：2022-03-24

申请号：PCT/EP2021/075038

申请日：2021-09-13

Applicant: BAYER AKTIENGESELLSCHAFT

Inventor： HEITMEIER, Stefan ,  GLUNZ, Julia ,  FISCHER, Melanie ,  SCHULENBURG, Cindy ,  JÖRISSEN, Hannah ,  THIEL, Christoph ,  WILMEN, Andreas ,  WEBER, Ernst

IPC: C07K16/38 ,  A61P7/02 ,  A61P9/00 ,  A61P11/00 ,  G01N33/86

Abstract: The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and/or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.

公开(公告)号：WO2021007338A1

公开(公告)日：2021-01-14

申请号：PCT/US2020/041228

申请日：2020-07-08

Applicant: IMCARE BIOTECH, LLC.

Inventor： LU, Xuanyong ,  LU, Felix

IPC: A61P35/00 ,  C07K16/38

Abstract: Anti-AS-SPIK antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to diagnose and/or treat disorders characterized by the expression of AS-SPIK (e.g., liver cancer). Diagnostic methods and kits comprising the anti-AS-SPIK antibodies are also disclosed.

公开(公告)号：WO2019035055A1

公开(公告)日：2019-02-21

申请号：PCT/IB2018/056198

申请日：2018-08-16

Applicant: JANSSEN PHARMACEUTICA NV ,  CHINTALA, Madhu

Inventor： CHINTALA, Madhu ,  CHINTALA, Madhu ,  BERNHOLZ, Juliane ,  CONNOLLY, Thomas ,  PETERS, Gary

IPC: A61K39/395 ,  C07K16/38 ,  A61P7/02

CPC classification number: C07K16/38 ,  A61K39/3955 ,  A61K2039/505 ,  A61P7/02 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to isolated anti-thrombin antibodies that recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These anti-thrombin antibody molecules may be useful for treating or inhibiting thrombotic and/or embolic disorders and other conditions mediated by thrombin. In particular, the present invention relates to use of the anti-thrombin antibody molecules in combination with one or more antiplatelet agents.

公开(公告)号：WO2018117244A1

公开(公告)日：2018-06-28

申请号：PCT/JP2017/046044

申请日：2017-12-21

Applicant: 第一三共株式会社

Inventor： 西宮　大祐 ,  橋本　隆二 ,  佐藤　俊之 ,  木村　貴子 ,  山崎　淳史 ,  井上　達也

IPC: C12N15/09 ,  A61K38/55 ,  A61K45/00 ,  A61K45/06 ,  A61P9/00 ,  A61P19/02 ,  A61P27/02 ,  A61P29/00 ,  A61P43/00 ,  C07K16/38 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02 ,  C12Q1/37

Abstract: 新規ペプチドを提供すること　配列番号３０で示されるアミノ酸配列を含み、且つ、プロテアーゼ活性を阻害するペプチド。